NCT05618587

Effect of Lithium Therapy on Long COVID Symptoms

Effect of Low-dose Lithium Therapy on Long COVID Symptoms: a Randomized Controlled Trial.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 52 (actual)
• Sponsor: State University of New York at Buffalo · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

This study will assess low-dose lithium's effects on several different symptoms experienced by long COVID patients.

Detailed description

In this double-blind, placebo-controlled study, 50 patients with long COVID will be randomly assigned to either low-dose oral lithium or placebo therapy for three weeks. After the double-blind study phase, all patients will be provided with lithium therapy for two additional weeks. Study visits will occur at baseline and after the three-week double-blind study phase.

Conditions

• Long COVID

Interventions

Type	Name	Description
DRUG	Lithium	Lithium has multiple mechanisms of action including anti-inflammatory actions, which may be relevant for treating long COVID.
DRUG	Placebo	Inactive pill

Timeline

• Start date: 2022-11-28
• Primary completion: 2023-07-21
• Completion: 2023-07-21
• First posted: 2022-11-16
• Last updated: 2025-03-05
• Results posted: 2025-03-05

Locations

1 site across 1 country: United States